MRC2	B-GP
Expression	O
Correlates	O
with	O
TGFβ1	B-GP
and	O
Survival	O
in	O
Hepatocellular	B-DS
Carcinoma	I-DS

These	O
authors	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

MRC2	B-GP
(	O
Mannose	B-GP
Receptor	I-GP
C	I-GP
Type	I-GP
2	I-GP
)	O
is	O
a	O
constitutively	O
recycling	O
endocytic	B-GP
receptor	I-GP
belonging	O
to	O
the	O
mannose	B-GP
receptor	I-GP
family	O
,	O
which	O
has	O
been	O
found	O
to	O
be	O
closely	O
involved	O
with	O
cancer	B-DS
metastasis	O
.	O

This	O
study	O
attempted	O
to	O
determine	O
MRC2	B-GP
expression	O
on	O
hepatocellular	B-DS
carcinoma	I-DS
(	O
HCC	B-DS
)	O
and	O
its	O
significance	O
on	O
postsurgical	O
prognosis	O
of	O
HCCs	B-DS
.	O

The	O
expression	O
of	O
both	O
MRC2	B-GP
and	O
transforming	B-GP
growth	I-GP
factor	I-GP
(	O
TGFβ1	B-GP
)	O
was	O
detected	O
in	O
tumor	B-DS
tissues	O
and	O
adjacent	O
liver	O
tissues	O
from	O
96	O
HCCs	B-DS
by	O
immunohistochemistry	O
staining	O
,	O
and	O
it	O
was	O
found	O
that	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
was	O
significantly	O
higher	O
than	O
in	O
adjacent	O
liver	O
tissues	O
.	O

HCCs	B-DS
with	O
higher	O
MRC2	B-GP
expression	O
had	O
worse	O
prognosis	O
after	O
liver	O
resection	O
.	O

Univariate	O
analysis	O
showed	O
that	O
advanced	O
TNM	O
staging	O
of	O
HCC	B-DS
,	O
higher	O
Edmonson	O
-	O
Steiner	O
classification	O
,	O
intrahepatic	O
metastases	O
,	O
portal	O
vein	O
invasion	O
,	O
higher	O
MRC2	B-GP
and	O
higher	O
TGFβ1	B-GP
were	O
the	O
poor	O
prognostic	O
factors	O
.	O

Furthermore	O
,	O
multivariate	O
analysis	O
revealed	O
that	O
intrahepatic	O
metastases	O
,	O
higher	O
MRC2	B-GP
and	O
higher	O
TGFβ1	B-GP
were	O
the	O
independent	O
prognostic	O
factors	O
.	O

TGFβ1	B-GP
treatment	O
up	O
-	O
regulated	O
MRC2	B-GP
expression	O
,	O
cell	O
migration	O
and	O
invasion	O
of	O
Huh7	O
cells	O
notably	O
.	O

In	O
addition	O
,	O
knockdown	O
of	O
MRC2	B-GP
repressed	O
the	O
effect	O
of	O
TGFβ1	B-GP
on	O
cell	O
migration	O
and	O
invasion	O
.	O

These	O
data	O
suggest	O
that	O
MRC2	B-GP
overexpression	O
predicts	O
poor	O
prognosis	O
of	O
HCCs	B-DS
after	O
liver	O
resection	O
and	O
MRC2	B-GP
potentially	O
contributed	O
to	O
TGFβ1	B-GP
-	O
driven	O
up	O
-	O
regulation	O
of	O
cell	O
migration	O
and	O
invasion	O
in	O
HCC	B-DS
.	O

1	O
.	O

Introduction	O

Hepatocellular	B-DS
carcinoma	I-DS
(	O
HCC	B-DS
)	O
is	O
one	O
of	O
the	O
highly	O
prevalent	O
malignant	O
diseases	O
and	O
is	O
the	O
third	O
leading	O
cause	O
of	O
cancer	B-DS
related	O
death	O
all	O
through	O
the	O
world	O
[	O
1	O
].	O

Incidences	O
of	O
the	O
disease	O
continue	O
to	O
increase	O
year	O
after	O
year	O
[	O
2	O
].	O

Because	O
there	O
are	O
no	O
typical	O
clinical	O
manifestations	O
and	O
high	O
metastasis	O
capacity	O
at	O
the	O
early	O
stage	O
,	O
most	O
HCC	B-DS
patients	O
cannot	O
receive	O
curative	O
surgical	O
treatments	O
including	O
radical	O
liver	O
resection	O
and	O
liver	O
transplantation	O
.	O

Additionally	O
,	O
due	O
to	O
its	O
high	O
recurrence	O
and	O
metastasis	O
characteristics	O
,	O
the	O
prognosis	O
of	O
HCC	B-DS
after	O
hepatic	O
resections	O
including	O
curative	O
one	O
and	O
palliative	O
one	O
is	O
dismal	O
.	O

Therefore	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
figure	O
out	O
the	O
underlying	O
molecular	O
mechanism	O
of	O
high	O
metastasis	O
capacity	O
of	O
HCC	B-DS
and	O
explore	O
the	O
novel	O
markers	O
predicting	O
HCC	B-DS
metastasis	O
efficaciously	O
in	O
clinic	O
.	O

Cancer	B-DS
metastasis	O
is	O
a	O
kind	O
of	O
tissue	O
remodeling	O
process	O
in	O
which	O
normal	O
tissue	O
in	O
the	O
local	O
organ	O
and	O
or	O
distant	O
organs	O
is	O
invaded	O
and	O
eventually	O
completely	O
replaced	O
by	O
cancer	B-DS
tissues	O
[	O
3	O
].	O

The	O
deposition	O
and	O
degradation	O
of	O
the	O
extracellular	O
matrix	O
are	O
the	O
critical	O
features	O
of	O
cancer	B-DS
metastasis	O
.	O

Among	O
them	O
,	O
there	O
are	O
multiple	O
functions	O
of	O
extracellular	O
matrix	O
degradation	O
on	O
tumor	B-DS
progression	O
including	O
:	O
(	O
1	O
)	O
providing	O
tumor	B-DS
mass	O
more	O
space	O
to	O
spread	O
;	O
(	O
2	O
)	O
liberating	O
more	O
latent	O
growth	O
factors	O
from	O
extracellular	O
matrix	O
and	O
activating	O
oncogenic	O
cell	O
signalings	O
in	O
neighboring	O
tumor	B-DS
cells	O
;	O
(	O
3	O
)	O
facilitating	O
the	O
formation	O
of	O
neovasculature	O
within	O
tumor	B-DS
mass	O
;	O
(	O
4	O
)	O
abolishing	O
the	O
restrictions	O
of	O
tumor	B-DS
cell	O
proliferation	O
from	O
extracellular	O
matrix	O
[	O
4	O
].	O

Thus	O
,	O
it	O
is	O
crucial	O
to	O
demonstrate	O
the	O
mechanism	O
of	O
extracellular	O
matrix	O
degradation	O
.	O

Transforming	B-GP
growth	I-GP
factor	I-GP
(	O
TGFβ1	B-GP
)	O
is	O
a	O
pleiotropic	O
cytokine	B-GP
which	O
contributes	O
to	O
wound	O
healing	O
,	O
angiogenesis	O
,	O
fibrosis	O
and	O
cancer	B-DS
[	O
5	O
].	O

It	O
was	O
first	O
identified	O
in	O
mammary	O
epithelial	O
development	O
by	O
Daniel	O
and	O
his	O
colleagues	O
in	O
1987	O
[	O
6	O
].	O

A	O
growing	O
body	O
of	O
evidences	O
showed	O
that	O
TGFβ1	B-GP
functions	O
as	O
either	O
a	O
tumor	B-DS
suppressor	O
or	O
a	O
tumor	B-DS
promoter	O
[	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
11	O
,	O
12	O
]	O
via	O
both	O
SMAD	B-GP
(	O
drosophila	B-OG
mothers	B-GP
against	I-GP
decapentaplegic	I-GP
protein	I-GP
)-	O
dependent	O
and	O
SMAD	B-GP
-	O
independent	O
cascades	O
.	O

In	O
fact	O
,	O
the	O
multifunctional	O
activities	O
of	O
TGFβ1	B-GP
depends	O
on	O
the	O
stage	O
of	O
carcinogenesis	O
.	O

In	O
normal	O
epithelia	O
,	O
it	O
acts	O
as	O
tumor	B-DS
repressors	O
through	O
both	O
inhibiting	O
cell	O
proliferation	O
and	O
inducing	O
apoptosis	O
,	O
whereas	O
accelerating	O
progression	O
of	O
established	O
cancers	B-DS
via	O
activating	O
various	O
oncogenic	O
cell	O
signals	O
and	O
inducing	O
EMT	O
directly	O
[	O
11	O
,	O
13	O
,	O
14	O
].	O

Generally	O
,	O
the	O
tumor	B-DS
promoter	O
function	O
of	O
TGFβ1	B-GP
in	O
the	O
context	O
of	O
cancer	B-DS
progression	O
results	O
from	O
two	O
actions	O
including	O
losing	O
its	O
inhibitory	O
effect	O
on	O
carcinogenesis	O
and	O
awaking	O
its	O
oncogenic	O
function	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
explore	O
the	O
key	O
factors	O
which	O
play	O
an	O
important	O
roles	O
in	O
the	O
conversion	O
of	O
TGFβ1	B-GP
function	O
from	O
a	O
tumor	B-DS
suppressor	O
to	O
a	O
tumor	B-DS
promoter	O
.	O

Mannose	B-GP
Receptor	I-GP
C	I-GP
Type	I-GP
2	I-GP
(	O
MRC2	B-GP
),	O
also	O
known	O
as	O
uPARAP	B-GP
/	O
Endo180	B-GP
,	O
is	O
a	O
constitutively	O
recycling	O
endocytic	B-GP
receptor	I-GP
belonging	O
to	O
the	O
mannose	B-GP
receptor	I-GP
family	O
[	O
15	O
].	O

Through	O
the	O
endocytic	O
function	O
,	O
MRC2	B-GP
is	O
found	O
to	O
bind	O
and	O
internalize	O
both	O
intact	O
and	O
degraded	O
collagens	B-GP
and	O
in	O
turn	O
take	O
part	O
in	O
the	O
turnover	O
of	O
collagens	B-GP
in	O
both	O
cytomembrane	O
and	O
extracellular	O
matrix	O
[	O
16	O
].	O

Recently	O
,	O
there	O
have	O
been	O
accumulating	O
reports	O
showing	O
that	O
MRC2	B-GP
is	O
aberrantly	O
up	O
-	O
regulated	O
in	O
a	O
variety	O
of	O
cancers	B-DS
and	O
closely	O
involved	O
in	O
cancer	B-DS
metastasis	O
including	O
breast	B-DS
cancer	I-DS
[	O
17	O
,	O
18	O
],	O
prostate	B-DS
cancer	I-DS
[	O
19	O
],	O
head	O
stroma	O
,	O
and	O
neck	B-DS
cancer	I-DS
[	O
20	O
].	O

However	O
,	O
the	O
expression	O
of	O
MRC2	B-GP
and	O
its	O
role	O
in	O
HCC	B-DS
remain	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
attempted	O
to	O
address	O
the	O
following	O
questions	O
:	O
(	O
1	O
)	O
Is	O
MRC2	B-GP
expression	O
up	O
-	O
regulated	O
aberrantly	O
in	O
HCC	B-DS
tissues	O
compared	O
to	O
adjacent	O
liver	O
tissues	O
?	O

(	O
2	O
)	O
What	O
is	O
the	O
relationship	O
between	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
and	O
HCC	B-DS
prognosis	O
after	O
liver	O
resection	O
?	O

(	O
3	O
)	O
What	O
is	O
the	O
correlation	O
between	O
TGFβ1	B-GP
and	O
MRC2	B-GP
?	O

(	O
4	O
)	O
Is	O
MRC2	B-GP
attributed	O
to	O
the	O
oncogenic	O
effect	O
of	O
TGFβ1	B-GP
in	O
HCC	B-DS
?	O

2	O
.	O

Results	O
and	O
Discussion	O

2	O
.	O
1	O
.	O

Mannose	B-GP
Receptor	I-GP
C	I-GP
Type	I-GP
2	I-GP
(	O
MRC2	B-GP
)	O
Was	O
Over	O
-	O
Expressed	O
in	O
Hepatocellular	B-DS
Carcinoma	I-DS
(	O
HCC	B-DS
)	O
Tissues	O
and	O
Associated	O
with	O
Poor	O
Prognosis	O
after	O
Liver	O
Resection	O

To	O
observe	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
,	O
immunohistochemistry	O
(	O
IHC	O
)	O
staining	O
assays	O
were	O
carried	O
out	O
and	O
it	O
was	O
found	O
that	O
MRC2	B-GP
protein	O
located	O
in	O
both	O
cell	O
membrane	O
and	O
cytoplasm	O
,	O
as	O
shown	O
in	O
Figure	O
1a	O
.	O

By	O
analyzing	O
the	O
IHC	O
score	O
using	O
the	O
Mann	O
–	O
Whitney	O
U	O
test	O
,	O
we	O
found	O
that	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
was	O
significantly	O
higher	O
than	O
one	O
in	O
adjacent	O
liver	O
tissues	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
1c	O
).	O

We	O
also	O
examined	O
MRC2	B-GP
expression	O
by	O
western	O
immunoblotting	O
in	O
3	O
pairs	O
of	O
representative	O
HCC	B-DS
tissues	O
and	O
adjacent	O
liver	O
tissues	O
.	O

As	O
shown	O
in	O
Figure	O
1b	O
,	O
there	O
was	O
significantly	O
more	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
than	O
in	O
adjacent	O
liver	O
tissues	O
.	O

The	O
relationship	O
between	O
MRC2	B-GP
and	O
the	O
clinicopathological	O
parameters	O
of	O
the	O
96	O
HCCs	B-DS
was	O
statistically	O
assessed	O
and	O
the	O
results	O
were	O
listed	O
in	O
Table	O
1	O
.	O

The	O
expression	O
of	O
MRC2	B-GP
was	O
significantly	O
associated	O
with	O
intrahepatic	O
metastases	O
(	O
r	O
=	O
0	O
.	O
485	O
,	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
portal	O
vein	O
invasion	O
(	O
r	O
=	O
0	O
.	O
214	O
,	O
p	O
=	O
0	O
.	O
002	O
).	O

However	O
,	O
there	O
was	O
no	O
significant	O
correlation	O
between	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
and	O
gender	O
(	O
r	O
=	O
−	O
0	O
.	O
16	O
,	O
p	O
=	O
0	O
.	O
062	O
),	O
age	O
(	O
r	O
=	O
0	O
.	O
344	O
,	O
p	O
=	O
0	O
.	O
121	O
),	O
HBV	B-DS
infection	I-DS
(	O
r	O
=	O
0	O
.	O
312	O
,	O
p	O
=	O
0	O
.	O
075	O
),	O
liver	B-DS
cirrhosis	I-DS
(	O
r	O
=	O
0	O
.	O
12	O
,	O
p	O
=	O
0	O
.	O
063	O
),	O
serumα	O
-	O
fetoprotein	O
(	O
AFP	B-GP
)	O
level	O
(	O
r	O
=	O
0	O
.	O
322	O
,	O
p	O
=	O
0	O
.	O
130	O
),	O
tumor	B-DS
size	O
(	O
r	O
=	O
0	O
.	O
271	O
,	O
p	O
=	O
0	O
.	O
091	O
),	O
Edmonson	O
–	O
Steiner	O
classification	O
(	O
r	O
=	O
0	O
.	O
332	O
,	O
p	O
=	O
0	O
.	O
130	O
)	O
and	O
vasculature	O
invasion	O
(	O
r	O
=	O
0	O
.	O
070	O
,	O
p	O
=	O
0	O
.	O
071	O
).	O

(	O
a	O
)	O
(	O
I	O
)	O
The	O
representative	O
immunohistochemistry	O
(	O
IHC	O
)	O
staining	O
of	O
MRC2	B-GP
in	O
HCC	B-DS
tissues	O
.	O

MRC2	B-GP
protein	O
located	O
in	O
both	O
cell	O
membrane	O
(	O
black	O
arrow	O
)	O
and	O
cytoplasm	O
(	O
white	O
arrow	O
);	O
(	O
II	O
)	O
The	O
representative	O
IHC	O
staining	O
of	O
MRC2	B-GP
in	O
adjacent	O
liver	O
tissues	O
;	O
(	O
III	O
)	O
The	O
negative	O
staining	O
of	O
MRC2	B-GP
in	O
HCC	B-DS
tissues	O
;	O
(	O
b	O
)	O
The	O
western	O
immunoblotting	O
results	O
of	O
MRC2	B-GP
in	O
3	O
pairs	O
of	O
representative	O
HCC	B-DS
tissues	O
(	O
T	O
)	O
and	O
adjacent	O
liver	O
tissues	O
(	O
N	O
);	O
(	O
c	O
)	O
The	O
IHC	O
scores	O
of	O
MRC2	B-GP
in	O
HCC	B-DS
tissues	O
were	O
significantly	O
higher	O
than	O
one	O
in	O
adjacent	O
liver	O
tissues	O
(	O
p	O
<	O
0	O
.	O
001	O
);	O
and	O
(	O
d	O
)	O
The	O
comparison	O
of	O
Kaplan	O
–	O
Meier	O
survival	O
curves	O
showed	O
that	O
patients	O
with	O
higher	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
had	O
worse	O
prognosis	O
after	O
liver	O
resection	O
(	O
HR	O
=	O
3	O
.	O
071	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
357	O
,	O
6	O
.	O
951	O
;	O
p	O
=	O
0	O
.	O
007	O
).	O

Correlation	O
between	O
the	O
Clinicopathological	O
Parameters	O
and	O
Mannose	B-GP
Receptor	I-GP
C	I-GP
Type	I-GP
2	I-GP
(	O
MRC2	B-GP
)	O
Expression	O
in	O
96	O
HCCs	B-DS
.	O

Clinicopathological	O
Parameters	O

No	O
.	O
of	O
Higher	O
MRC2	B-GP
Expression	O
in	O
HCC	B-DS
Tissues	O

r	O
-	O
Value	O

p	O
-	O
Value	O

Gender	O

Female	O
(	O
n	O
=	O
39	O
)	O

28	O

−	O
0	O
.	O
16	O

0	O
.	O
062	O

Male	O
(	O
n	O
=	O
57	O
)	O

34	O

Age	O

>	O
50	O
(	O
n	O
=	O
49	O
)	O

43	O

0	O
.	O
344	O

0	O
.	O
121	O

<	O
50	O
(	O
n	O
=	O
47	O
)	O

19	O

HBV	B-DS
Infection	I-DS

Yes	O
(	O
n	O
=	O
76	O
)	O

59	O

0	O
.	O
312	O

0	O
.	O
075	O

No	O
(	O
n	O
=	O
20	O
)	O

3	O

Liver	B-DS
Cirrhosis	I-DS

Yes	O
(	O
n	O
=	O
89	O
)	O

61	O

0	O
.	O
12	O

0	O
.	O
063	O

No	O
(	O
n	O
=	O
7	O
)	O

1	O

High	O
Serum	O
AFP	B-GP
Level	O

>	O
400	O
ng	O
/	O
mL	O

38	O

0	O
.	O
322	O

0	O
.	O
130	O

<	O
400	O
ng	O
/	O
mL	O

24	O

Tumor	B-DS
Size	O

>	O
5	O
cm	O

40	O

0	O
.	O
271	O

0	O
.	O
091	O

<	O
5	O
cm	O

22	O

Intrahepatic	O
Metastases	O

Yes	O
(	O
n	O
=	O
18	O
)	O

16	O

0	O
.	O
485	O

0	O
.	O
005	O

No	O
(	O
n	O
=	O
78	O
)	O

46	O

Portal	O
Vein	O
Invasion	O

Yes	O
(	O
n	O
=	O
9	O
)	O

9	O

0	O
.	O
214	O

0	O
.	O
002	O

No	O
(	O
n	O
=	O
87	O
)	O

53	O

Portal	O
Vein	O
Invasion	O

Yes	O
(	O
n	O
=	O
9	O
)	O

9	O

0	O
.	O
214	O

0	O
.	O
002	O

No	O
(	O
n	O
=	O
87	O
)	O

53	O

Edmonson	O
–	O
Steiner	O
Classification	O

I	O
and	O
II	O
(	O
n	O
=	O
34	O
)	O

24	O

0	O
.	O
332	O

0	O
.	O
130	O

III	O
and	O
IV	O
(	O
n	O
=	O
62	O
)	O

38	O

Advanced	O
TNM	O
Stage	O

I	O
and	O
II	O
(	O
n	O
=	O
52	O
)	O

26	O

0	O
.	O
151	O

0	O
.	O
032	O

III	O
and	O
IV	O
(	O
n	O
=	O
44	O
)	O

36	O

Vasculature	O
Invasion	O
*	O

Yes	O
(	O
n	O
=	O
12	O
)	O

7	O

0	O
.	O
070	O

0	O
.	O
071	O

No	O
(	O
n	O
=	O
84	O
)	O

55	O

*	O
Vasculature	O
invasion	O
means	O
microscopic	O
vein	O
invasion	O
;	O
AFP	B-GP
:	O
serumα	O
-	O
fetoprotein	O
;	O
TNM	O
:	O
TNM	O
Classification	O
for	O
Hepatocellular	B-DS
Carcinoma	I-DS
.	O

We	O
obtained	O
the	O
follow	O
-	O
up	O
information	O
from	O
72	O
of	O
96	O
HCC	B-DS
cases	O
(	O
75	O
%).	O

The	O
median	O
time	O
of	O
follow	O
-	O
up	O
was	O
18	O
months	O
.	O

We	O
compared	O
the	O
Kaplan	O
-	O
Meier	O
survival	O
curves	O
between	O
the	O
high	O
MRC2	B-GP
group	O
,	O
in	O
which	O
HCC	B-DS
tissues	O
had	O
more	O
MRC2	B-GP
expression	O
than	O
adjacent	O
liver	O
tissues	O
,	O
and	O
in	O
the	O
low	O
MRC2	B-GP
group	O
and	O
found	O
that	O
the	O
high	O
MRC2	B-GP
group	O
had	O
clearly	O
worse	O
prognosis	O
after	O
liver	O
resection	O
than	O
the	O
low	O
MRC2	B-GP
group	O
(	O
HR	O
=	O
3	O
.	O
071	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
357	O
,	O
6	O
.	O
951	O
;	O
p	O
=	O
0	O
.	O
007	O
;	O
Figure	O
1d	O
),	O
which	O
pointed	O
out	O
that	O
MRC2	B-GP
over	O
-	O
expression	O
in	O
HCC	B-DS
tissues	O
was	O
an	O
important	O
factor	O
associated	O
with	O
poor	O
outcome	O
after	O
liver	O
resection	O
.	O

After	O
univariate	O
analysis	O
,	O
it	O
was	O
found	O
that	O
advanced	O
TNM	O
staging	O
,	O
higher	O
Edmonson	O
–	O
Steiner	O
classification	O
,	O
intrahepatic	O
metastases	O
,	O
portal	O
vein	O
invasion	O
,	O
higher	O
MRC2	B-GP
and	O
higher	O
TGFβ1	B-GP
were	O
the	O
poor	O
prognostic	O
factors	O
.	O

Furthermore	O
,	O
multivariate	O
analysis	O
revealed	O
that	O
intrahepatic	O
metastases	O
,	O
higher	O
MRC2	B-GP
and	O
higher	O
TGFβ1	B-GP
were	O
the	O
independent	O
prognostic	O
factors	O
for	O
HCC	B-DS
patients	O
after	O
liver	O
resection	O
(	O
as	O
shown	O
in	O
Table	O
2	O
).	O

Cox	O
proportional	O
-	O
hazard	O
regression	O
analysis	O
of	O
the	O
relationship	O
between	O
clinicopathologic	O
parameters	O
and	O
overall	O
survival	O
rate	O
of	O
HCC	B-DS
Patients	O
after	O
liver	O
resection	O
.	O

Clinicopathologic	O
Parameters	O

Unvariate	O
Analysis	O

Multivariate	O
Analysis	O

RR	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
Value	O

RR	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
Value	O

Intrahepatic	O
Metastases	O

3	O
.	O
120	O
(	O
2	O
.	O
132	O
–	O
6	O
.	O
324	O
)	O

0	O
.	O
001	O

2	O
.	O
975	O
(	O
1	O
.	O
587	O
–	O
4	O
.	O
525	O
)	O

0	O
.	O
003	O

Higher	O
MRC2	B-GP
Expression	O
in	O
HCC	B-DS
Tissue	O

1	O
.	O
856	O
(	O
1	O
.	O
323	O
–	O
2	O
.	O
241	O
)	O

0	O
.	O
012	O

2	O
.	O
035	O
(	O
1	O
.	O
785	O
–	O
2	O
.	O
995	O
)	O

0	O
.	O
015	O

Higher	O
TGFβ1	B-GP
Expression	O
in	O
HCC	B-DS
Tissue	O

1	O
.	O
697	O
(	O
1	O
.	O
022	O
–	O
1	O
.	O
975	O
)	O

0	O
.	O
030	O

1	O
.	O
882	O
(	O
1	O
.	O
211	O
–	O
2	O
.	O
214	O
)	O

0	O
.	O
022	O

2	O
.	O
2	O
.	O

Transforming	B-GP
Growth	I-GP
Factor	I-GP
(	O
TGFβ1	B-GP
)	O
Was	O
Up	O
-	O
Regulated	O
in	O
HCC	B-DS
Tissues	O
and	O
Associated	O
with	O
MRC2	B-GP
Positively	O

To	O
determine	O
the	O
relationship	O
between	O
TGFβ1	B-GP
and	O
MRC2	B-GP
in	O
HCC	B-DS
tissues	O
,	O
we	O
also	O
observed	O
TGFβ1	B-GP
expression	O
in	O
both	O
HCC	B-DS
tissues	O
and	O
adjacent	O
liver	O
tissues	O
by	O
IHC	O
staining	O
.	O

As	O
shown	O
in	O
Figure	O
2a	O
,	O
the	O
majority	O
of	O
positive	O
TGFβ1	B-GP
staining	O
cells	O
showed	O
diffused	O
cytoplasmic	O
staining	O
.	O

After	O
analyzing	O
the	O
IHC	O
scores	O
by	O
the	O
Mann	O
–	O
Whitney	O
test	O
,	O
we	O
found	O
that	O
the	O
expression	O
of	O
TGFβ1	B-GP
in	O
HCC	B-DS
tissues	O
was	O
apparently	O
more	O
than	O
one	O
in	O
adjacent	O
liver	O
tissues	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
2c	O
).	O

Additionally	O
,	O
expression	O
of	O
TGF	B-GP
β1	I-GP
in	O
the	O
representative	O
HCC	B-DS
tissues	O
was	O
found	O
apparently	O
more	O
than	O
that	O
in	O
the	O
matching	O
adjacent	O
liver	O
tissues	O
(	O
shown	O
in	O
Figure	O
2b	O
).	O

The	O
Spearmen	O
rank	O
test	O
also	O
verified	O
that	O
there	O
was	O
a	O
significantly	O
positive	O
correlation	O
between	O
TGFβ1	B-GP
and	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
(	O
r	O
=	O
0	O
.	O
347	O
,	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
2d	O
),	O
which	O
initially	O
indicated	O
that	O
TGFβ1	B-GP
could	O
be	O
involved	O
in	O
aberrant	O
over	O
-	O
expression	O
of	O
MRC2	B-GP
in	O
HCC	B-DS
.	O

2	O
.	O
3	O
.	O

TGFβ1	B-GP
Treatment	O
Up	O
-	O
Regulated	O
MRC2	B-GP
Expression	O
and	O
Enhanced	O
Cell	O
Mobility	O
and	O
Invasion	O
of	O
HCC	B-DS
Cells	O

To	O
examine	O
further	O
whether	O
TGFβ1	B-GP
take	O
part	O
in	O
aberrant	O
MRC2	B-GP
over	O
-	O
expression	O
in	O
HCC	B-DS
,	O
we	O
treated	O
Huh7	O
cells	O
with	O
recombinant	O
human	B-OG
TGFβ1	B-GP
protein	O
in	O
vitro	O
.	O

It	O
was	O
found	O
that	O
MRC2	B-GP
expression	O
of	O
Huh7	O
cells	O
was	O
increased	O
at	O
the	O
level	O
of	O
both	O
mRNA	O
and	O
protein	O
48	O
h	O
after	O
TGFβ1	B-GP
treatment	O
at	O
the	O
concentration	O
of	O
10	O
ng	O
/	O
mL	O
(	O
Figure	O
3a	O
).	O

The	O
scratch	O
wound	O
healing	O
migration	O
assay	O
showed	O
that	O
the	O
migration	O
rate	O
of	O
Huh7	O
cells	O
stimulated	O
by	O
TGFβ1	B-GP
(	O
TGFβ1	B-GP
group	O
)	O
was	O
obviously	O
higher	O
than	O
that	O
of	O
control	O
Huh7	O
cells	O
(	O
Control	O
group	O
)	O
at	O
24	O
and	O
48	O
h	O
after	O
scratching	O
(	O
p	O
=	O
0	O
.	O
005	O
and	O
p	O
=	O
0	O
.	O
002	O
,	O
respectively	O
;	O
Figure	O
3b	O
).	O

In	O
the	O
invasion	O
assay	O
,	O
there	O
were	O
94	O
±	O
6	O
Huh7	O
cells	O
per	O
field	O
crossing	O
the	O
Matrigel	O
gel	O
and	O
chamber	O
filter	O
in	O
TGFβ1	B-GP
group	O
,	O
whereas	O
65	O
±	O
4	O
Huh7	O
cells	O
per	O
field	O
in	O
Control	O
group	O
(	O
p	O
=	O
0	O
.	O
002	O
;	O
Figure	O
3c	O
).	O

To	O
further	O
verify	O
the	O
regulatory	O
function	O
of	O
TGFβ1	B-GP
on	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
cells	O
,	O
we	O
treated	O
Hep3B	O
cells	O
with	O
TGF	B-GP
β1	I-GP
.	O

Similarly	O
,	O
MRC2	B-GP
expression	O
was	O
found	O
to	O
be	O
increased	O
apparently	O
by	O
both	O
qRT	O
-	O
PCR	O
and	O
western	O
immunoblotting	O
,	O
as	O
shown	O
in	O
Figure	O
3d	O
.	O

The	O
migration	O
and	O
invasion	O
capacities	O
of	O
Hep3B	O
cells	O
were	O
also	O
promoted	O
by	O
TGFβ1	B-GP
treatment	O
(	O
Figure	O
3e	O
,	O
f	O
).	O

These	O
data	O
strongly	O
supported	O
that	O
TGFβ1	B-GP
promoted	O
tumor	B-DS
cell	O
mobility	O
and	O
invasion	O
and	O
meanwhile	O
induced	O
up	O
-	O
regulation	O
of	O
MRC2	B-GP
in	O
HCC	B-DS
cells	O
.	O

(	O
a	O
)	O
(	O
I	O
)	O
The	O
representative	O
IHC	O
staining	O
of	O
Transforming	B-GP
growth	I-GP
factor	I-GP
(	O
TGFβ1	B-GP
)	O
in	O
HCC	B-DS
tissues	O
;	O
(	O
II	O
)	O
The	O
representative	O
IHC	O
staining	O
of	O
TGFβ1	B-GP
in	O
adjacent	O
liver	O
tissues	O
;	O
(	O
III	O
)	O
The	O
negative	O
staining	O
of	O
TGFβ1	B-GP
in	O
HCC	B-DS
tissues	O
;	O
(	O
b	O
)	O
The	O
western	O
immunoblotting	O
results	O
of	O
TGFβ1	B-GP
in	O
3	O
pairs	O
of	O
representative	O
HCC	B-DS
tissues	O
(	O
T	O
)	O
and	O
adjacent	O
liver	O
tissues	O
(	O
N	O
);	O
(	O
c	O
)	O
The	O
IHC	O
scores	O
of	O
TGFβ1	B-GP
in	O
HCC	B-DS
tissues	O
were	O
significantly	O
higher	O
than	O
one	O
in	O
adjacent	O
liver	O
tissues	O
(	O
p	O
<	O
0	O
.	O
001	O
);	O
(	O
d	O
)	O
The	O
Spearmen	O
rank	O
test	O
showed	O
that	O
there	O
was	O
positive	O
correlation	O
between	O
TGFβ1	B-GP
and	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
(	O
r	O
=	O
0	O
.	O
347	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

(	O
a	O
)	O
As	O
assessed	O
by	O
both	O
western	O
immunoblotting	O
and	O
qRT	O
-	O
PCR	O
assays	O
,	O
TGFβ1	B-GP
treatment	O
leaded	O
to	O
up	O
-	O
regulation	O
of	O
MRC2	B-GP
in	O
Huh7	O
cells	O
significantly	O
;	O
(	O
b	O
)	O
TGFβ1	B-GP
treatment	O
promoted	O
migration	O
of	O
Huh7	O
cells	O
apparently	O
;	O
(	O
c	O
)	O
Invasion	O
capacity	O
of	O
Huh7	O
cells	O
was	O
significantly	O
enhanced	O
by	O
TGFβ1	B-GP
treatment	O
(	O
p	O
=	O
0	O
.	O
002	O
);	O
(	O
d	O
)	O
Both	O
qRT	O
-	O
PCR	O
and	O
western	O
immunoblotting	O
revealed	O
that	O
TGFβ1	B-GP
treatment	O
resulted	O
in	O
a	O
significant	O
increase	O
of	O
MRC2	B-GP
expression	O
in	O
Hep3B	O
cells	O
;	O
(	O
e	O
)	O
The	O
migration	O
ability	O
of	O
Hep3B	O
cells	O
was	O
increased	O
by	O
TGFβ1	B-GP
treatment	O
obviously	O
;	O
(	O
f	O
)	O
Millicell	O
invasion	O
chamber	O
assay	O
showed	O
that	O
TGFβ1	B-GP
treatment	O
up	O
-	O
regulated	O
invasion	O
ability	O
of	O
Hep3B	O
cells	O
clearly	O
.	O

2	O
.	O
4	O
.	O

Knockdown	O
of	O
MRC2	B-GP
Abolished	O
the	O
Effect	O
of	O
TGFβ1	B-GP
on	O
Cell	O
Mobility	O
and	O
Invasion	O

To	O
investigate	O
whether	O
MRC2	B-GP
plays	O
an	O
important	O
role	O
in	O
the	O
oncogenic	O
function	O
of	O
TGFβ1	B-GP
,	O
we	O
transfected	O
MRC2	B-GP
siRNA	O
into	O
Huh7	O
cells	O
one	O
day	O
before	O
TGFβ1	B-GP
treatment	O
in	O
order	O
to	O
repress	O
MRC2	B-GP
up	O
-	O
regulation	O
induced	O
by	O
TGFβ1	B-GP
.	O

The	O
qRT	O
-	O
PCR	O
and	O
western	O
immunoblotting	O
assays	O
both	O
confirmed	O
that	O
there	O
was	O
not	O
a	O
significant	O
increase	O
in	O
MRC2	B-GP
expression	O
of	O
Huh7	O
cells	O
after	O
TGFβ1	B-GP
treatment	O
(	O
Figure	O
4A	O
).	O

As	O
shown	O
in	O
Figure	O
4B	O
,	O
after	O
suppression	O
of	O
MRC2	B-GP
up	O
-	O
regulation	O
in	O
Huh7	O
cells	O
,	O
there	O
was	O
no	O
significant	O
difference	O
on	O
cell	O
migration	O
rate	O
between	O
TGFβ1	B-GP
group	O
and	O
Control	O
group	O
found	O
at	O
24	O
and	O
48	O
h	O
after	O
scratching	O
(	O
p	O
=	O
0	O
.	O
086	O
and	O
p	O
=	O
0	O
.	O
815	O
,	O
respectively	O
).	O

Consistently	O
,	O
the	O
number	O
of	O
cell	O
crossing	O
both	O
the	O
Matrigel	O
gel	O
and	O
chamber	O
filter	O
in	O
TGFβ1	B-GP
group	O
was	O
similar	O
with	O
that	O
in	O
Control	O
group	O
,	O
as	O
assessed	O
by	O
the	O
invasion	O
assay	O
(	O
p	O
=	O
0	O
.	O
449	O
;	O
Figure	O
4C	O
).	O

Hence	O
,	O
it	O
was	O
demonstrated	O
by	O
these	O
data	O
that	O
TGFβ1	B-GP
couldn	O
’	O
t	O
promote	O
mobility	O
and	O
invasion	O
ability	O
of	O
Huh7	O
cells	O
without	O
MRC2	B-GP
.	O

(	O
a	O
)	O
As	O
assessed	O
by	O
both	O
western	O
immunoblotting	O
and	O
qRT	O
-	O
PCR	O
assays	O
,	O
TGFβ1	B-GP
treatment	O
leaded	O
to	O
up	O
-	O
regulation	O
of	O
MRC2	B-GP
in	O
Huh7	O
cells	O
significantly	O
;	O
(	O
b	O
)	O
TGFβ1	B-GP
treatment	O
promoted	O
migration	O
of	O
Huh7	O
cells	O
apparently	O
;	O
and	O
(	O
c	O
)	O
Invasion	O
capacity	O
of	O
Huh7	O
cells	O
was	O
significantly	O
enhanced	O
by	O
TGFβ1	B-GP
treatment	O
(	O
p	O
=	O
0	O
.	O
001	O
).	O

2	O
.	O
5	O
.	O

TGFβ1	B-GP
/	O
Smad3	B-GP
Pathway	O
Regulated	O
MRC2	B-GP
Expression	O
in	O
HCC	B-DS
Directly	O

To	O
reveal	O
the	O
role	O
of	O
TGFβ1	B-GP
on	O
the	O
transcriptional	O
regulation	O
of	O
MRC2	B-GP
in	O
HCC	B-DS
,	O
we	O
identified	O
several	O
potential	O
Smad	B-GP
binding	O
sites	O
in	O
the	O
gene	O
promoter	O
of	O
MRC2	B-GP
using	O
MatInspector	O
professional	O
version	O
7	O
.	O
2	O
(	O
shown	O
in	O
Figure	O
5a	O
).	O

The	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
was	O
carried	O
out	O
to	O
test	O
the	O
direct	O
interaction	O
between	O
Smad	B-GP
and	O
the	O
MRC2	B-GP
promoter	O
in	O
Huh7	O
cells	O
treated	O
with	O
TGFβ1	B-GP
and	O
confirmed	O
that	O
Smad	B-GP
protein	O
was	O
bound	O
with	O
the	O
promoter	O
of	O
MRC2	B-GP
gene	O
in	O
the	O
nucleus	O
of	O
HCC	B-DS
cells	O
,	O
as	O
shown	O
in	O
Figure	O
5b	O
.	O

Hence	O
,	O
the	O
−	O
955	O
/−	O
401	O
bp	O
MRC2	B-GP
promoter	O
fragment	O
was	O
initially	O
identified	O
to	O
contain	O
the	O
Smad	B-GP
binding	O
sites	O
and	O
the	O
−	O
955	O
/−	O
1	O
bp	O
fragment	O
reconstituted	O
into	O
the	O
luciferase	B-GP
reporter	O
vector	O
,	O
pGL3	O
-	O
basic	O
.	O

To	O
address	O
whether	O
Smad3	B-GP
contributes	O
to	O
the	O
regulatory	O
effect	O
of	O
TGFβ1	B-GP
on	O
MRC2	B-GP
expression	O
,	O
we	O
treated	O
Huh7	O
cells	O
with	O
SIS3	O
,	O
a	O
kind	O
of	O
Smad3	B-GP
inhibitor	O
.	O

As	O
shown	O
in	O
Figure	O
5c	O
,	O
SIS3	O
treatment	O
resulted	O
in	O
an	O
apparent	O
decrease	O
in	O
MRC2	B-GP
promoter	O
activity	O
in	O
the	O
presence	O
of	O
TGFβ1	B-GP
,	O
as	O
assessed	O
by	O
luciferase	B-GP
report	O
assay	O
.	O

Thus	O
,	O
these	O
data	O
strongly	O
supported	O
that	O
TGFβ1	B-GP
/	O
Smad3	B-GP
signaling	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
MRC2	B-GP
in	O
HCC	B-DS
cells	O
via	O
mediating	O
positively	O
its	O
transcription	O
directly	O
.	O

(	O
a	O
)	O
Schematic	O
diagram	O
of	O
the	O
potential	O
Smad	B-GP
binding	O
sites	O
in	O
the	O
promoter	O
of	O
MRC2	B-GP
which	O
shows	O
there	O
are	O
six	O
neighboring	O
potential	O
Smad	B-GP
binding	O
sites	O
in	O
the	O
−	O
955	O
/−	O
401	O
bp	O
MRC2	B-GP
promoter	O
fragment	O
;	O
(	O
b	O
)	O
With	O
the	O
help	O
of	O
ChIP	O
assay	O
,	O
we	O
obtained	O
the	O
DNA	O
fragments	O
bound	O
with	O
Smad	B-GP
protein	O
in	O
the	O
nucleus	O
of	O
Huh7	O
cells	O
.	O

As	O
assessed	O
by	O
PCR	O
assay	O
,	O
TGFβ1	B-GP
treatment	O
increased	O
significantly	O
the	O
occupancy	O
of	O
Smad	B-GP
protein	O
in	O
the	O
MRC2	B-GP
promoter	O
;	O
(	O
c	O
)	O
The	O
luciferase	B-GP
reporter	O
assay	O
showed	O
that	O
TGFβ1	B-GP
treatment	O
leaded	O
to	O
more	O
MRC2	B-GP
luciferase	B-GP
activity	O
in	O
Huh7	O
cells	O
,	O
which	O
was	O
abolished	O
by	O
the	O
Smad3	B-GP
inhibitor	O
SIS3	O
.	O

These	O
data	O
strongly	O
demonstrated	O
that	O
Smad3	B-GP
was	O
involved	O
closely	O
in	O
the	O
regulatory	O
effect	O
of	O
TGFβ1	B-GP
on	O
MRC2	B-GP
expression	O
.	O

3	O
.	O

Experimental	O
Section	O

3	O
.	O
1	O
.	O

Patients	O
and	O
Specimens	O

There	O
were	O
a	O
total	O
of	O
96	O
HCC	B-DS
patients	O
recruited	O
in	O
this	O
investigation	O
which	O
underwent	O
liver	O
resection	O
in	O
our	O
hospital	O
from	O
2009	O
to	O
2010	O
.	O

HCC	B-DS
tissues	O
and	O
adjacent	O
liver	O
tissues	O
(>	O
2	O
cm	O
distance	O
to	O
the	O
resection	O
margin	O
)	O
were	O
obtained	O
and	O
kept	O
in	O
paraformaldehyde	O
immediately	O
.	O

The	O
diagnosis	O
of	O
all	O
patients	O
was	O
confirmed	O
by	O
pathologists	O
.	O

Not	O
all	O
patients	O
did	O
received	O
chemotherapy	O
or	O
embolization	O
therapy	O
before	O
surgery	O
.	O

Demographic	O
,	O
clinical	O
and	O
histopathological	O
information	O
were	O
collected	O
from	O
the	O
medical	O
records	O
and	O
shown	O
in	O
Table	O
1	O
.	O

The	O
follow	O
-	O
up	O
was	O
carried	O
out	O
by	O
our	O
group	O
to	O
analyze	O
postsurgical	O
over	O
-	O
all	O
survival	O
of	O
HCCs	B-DS
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
recruited	O
in	O
this	O
study	O
.	O

The	O
ethics	O
committee	O
of	O
the	O
First	O
Affiliated	O
Hospital	O
of	O
Xi	O
’	O
an	O
Jiaotong	O
University	O
approved	O
all	O
protocols	O
according	O
to	O
the	O
Helsinki	O
Declaration	O
of	O
2013	O
(	O
No	O
.	O
20080301	O
,	O
6	O
May	O
2008	O
).	O

3	O
.	O
2	O
.	O

Immunohistochemistry	O
Staining	O

Paraffin	O
-	O
embedded	O
tissue	O
sections	O
were	O
subjected	O
to	O
immunohistochemical	O
analysis	O
as	O
described	O
previously	O
[	O
21	O
].	O

The	O
primary	O
rabbit	B-OG
anti	O
-	O
MRC2	B-GP
antibody	B-GP
(	O
Catalog	O
No	O
.:	O
ab70132	O
)	O
and	O
primary	O
rabbit	B-OG
anti	O
-	O
TGFβ1	B-GP
antibody	B-GP
(	O
Catalog	O
No	O
.:	O
ab92486	O
)	O
were	O
both	O
obtained	O
from	O
Abcam	O
(	O
Cambridge	O
,	O
MA	O
,	O
USA	O
).	O

The	O
slides	O
were	O
dewaxed	O
and	O
dehydrated	O
.	O

After	O
rehydration	O
,	O
endogenous	O
peroxidase	B-GP
activity	O
was	O
blocked	O
for	O
30	O
min	O
using	O
a	O
methanol	O
solution	O
containing	O
0	O
.	O
3	O
%	O
hydrogen	O
peroxide	O
.	O

After	O
antigen	O
retrieval	O
in	O
citrate	O
buffer	O
,	O
we	O
blocked	O
all	O
slides	O
at	O
4	O
°	O
C	O
overnight	O
with	O
2	O
%	O
BSA	B-GP
.	O

The	O
slides	O
were	O
incubated	O
respectively	O
with	O
the	O
primary	O
antibodies	B-GP
targeting	O
MRC2	B-GP
and	O
TGFβ1	B-GP
overnight	O
at	O
4	O
°	O
C	O
.	O

Then	O
the	O
slides	O
were	O
washing	O
with	O
PBS	O
three	O
times	O
and	O
incubated	O
with	O
the	O
biotinylated	O
secondary	O
antibody	B-GP
which	O
was	O
purchased	O
from	O
Zhongshan	O
Goldenbridge	O
Biotechnology	O
Limited	O
Company	O
(	O
Beijing	O
,	O
China	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instruction	O
.	O

We	O
stained	O
the	O
slides	O
by	O
the	O
avidin	B-GP
–	O
biotin	O
–	O
peroxidase	B-GP
complex	O
(	O
SABC	O
)	O
method	O
.	O

The	O
slides	O
were	O
visualized	O
with	O
diaminobenzidine	O
and	O
counterstained	O
with	O
hematoxylin	O
.	O

Finally	O
,	O
tissues	O
were	O
dehydrated	O
in	O
alcohol	O
and	O
xylene	O
.	O

Two	O
experienced	O
pathologists	O
observed	O
all	O
slides	O
independently	O
to	O
assess	O
the	O
Edmonson	O
classification	O
clinical	O
TNM	O
grading	O
,	O
maximum	O
tumor	B-DS
diameter	O
and	O
the	O
results	O
of	O
IHC	O
assay	O
.	O

The	O
results	O
of	O
IHC	O
staining	O
were	O
evaluated	O
by	O
the	O
staining	O
intensity	O
and	O
the	O
percentage	O
of	O
specifically	O
positive	O
staining	O
tumor	B-DS
cells	O
.	O

Staining	O
intensity	O
was	O
classified	O
into	O
four	O
grades	O
:	O
0	O
,	O
none	O
;	O
1	O
,	O
weak	O
;	O
2	O
,	O
moderate	O
;	O
3	O
,	O
strong	O
.	O

The	O
percentage	O
of	O
specifically	O
positive	O
staining	O
tumor	B-DS
cells	O
was	O
given	O
with	O
the	O
following	O
grades	O
:	O
0	O
(<	O
5	O
%),	O
1	O
(	O
6	O
%–	O
25	O
%),	O
2	O
(	O
26	O
%–	O
50	O
%),	O
3	O
(	O
51	O
%–	O
75	O
%),	O
and	O
4	O
(>	O
75	O
%).	O

The	O
IHC	O
staining	O
score	O
was	O
expressed	O
by	O
multiplying	O
the	O
staining	O
intensity	O
and	O
the	O
percentage	O
of	O
specifically	O
positive	O
staining	O
tumor	B-DS
cells	O
.	O

The	O
IHC	O
score	O
of	O
>	O
1	O
was	O
considered	O
as	O
positive	O
staining	O
.	O

Each	O
slide	O
was	O
observed	O
for	O
10	O
independent	O
high	O
magnification	O
field	O
(×	O
400	O
)	O
to	O
get	O
the	O
mean	O
staining	O
score	O
.	O

The	O
representative	O
figures	O
of	O
each	O
score	O
were	O
shown	O
in	O
Figure	O
6	O
.	O

(	O
a	O
)	O
The	O
representative	O
MRC2	B-GP
staining	O
of	O
HCC	B-DS
tissue	O
with	O
1	O
score	O
;	O
(	O
b	O
)	O
the	O
representative	O
MRC2	B-GP
staining	O
of	O
HCC	B-DS
tissue	O
with	O
6	O
score	O
;	O
(	O
c	O
)	O
the	O
representative	O
MRC2	B-GP
staining	O
of	O
HCC	B-DS
tissue	O
with	O
12	O
score	O
;	O
(	O
d	O
)	O
the	O
representative	O
MRC2	B-GP
staining	O
of	O
adjacent	O
liver	O
tissue	O
with	O
1	O
score	O
;	O
(	O
e	O
)	O
the	O
representative	O
MRC2	B-GP
staining	O
of	O
adjacent	O
liver	O
tissue	O
with	O
6	O
score	O
.	O

3	O
.	O
3	O
.	O

Cell	O
Culture	O
and	O
TGFβ1	B-GP
Treatment	O

Huh7	O
cell	O
line	O
was	O
a	O
kind	O
gift	O
from	O
Kefeng	O
Dou	O
(	O
Department	O
of	O
Hepatobiliary	O
Surgery	O
,	O
Xijing	O
Hospital	O
,	O
Fourth	O
Military	O
Medical	O
University	O
,	O
Xi	O
’	O
an	O
,	O
China	O
)	O
and	O
cultured	O
with	O
DMEM	O
medium	O
with	O
10	O
%	O
FBS	O
at	O
37	O
°	O
C	O
in	O
a	O
humidified	O
atmosphere	O
of	O
95	O
%	O
air	O
and	O
5	O
%	O
CO2	O
.	O

For	O
TGFβ1	B-GP
treatment	O
,	O
Huh7	O
cells	O
were	O
cultured	O
with	O
1	O
%	O
FBS	O
for	O
24	O
h	O
and	O
stimulated	O
with	O
10	O
ng	O
/	O
mL	O
of	O
TGFβ1	B-GP
for	O
48	O
h	O
.	O

3	O
.	O
4	O
.	O

RNAi	O
Transfections	O

We	O
purchased	O
the	O
siRNAs	O
against	O
MRC2	B-GP
(	O
Catalog	O
No	O
.:	O
sc	O
-	O
62276	O
)	O
and	O
the	O
scrambled	O
siRNAs	O
(	O
Catalog	O
No	O
.:	O
sc	O
-	O
37007	O
)	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
).	O

Huh7	O
cells	O
were	O
plated	O
in	O
six	O
-	O
well	O
plates	O
at	O
the	O
concentration	O
of	O
0	O
.	O
2	O
×	O
106	O
per	O
well	O
and	O
cultured	O
overnight	O
.	O

Then	O
Huh7	O
cells	O
in	O
each	O
well	O
were	O
transfected	O
with	O
100	O
nM	O
siRNAs	O
using	O
Lipofectamine	O
RNAi	O
MAX	O
Reagent	O
(	O
Invitrogen	O
,	O
CA	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacture	O
’	O
s	O
recommendations	O
.	O

The	O
cells	O
were	O
used	O
for	O
further	O
experiments	O
at	O
48	O
h	O
after	O
transfection	O
.	O

3	O
.	O
5	O
.	O

Western	O
Immunoblotting	O

Western	O
immunoblotting	O
assay	O
was	O
carried	O
out	O
as	O
described	O
previously	O
[	O
22	O
].	O

Briefly	O
speaking	O
,	O
30	O
mg	O
denatured	O
protein	O
samples	O
were	O
separated	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
PAGE	O
)	O
and	O
then	O
transferred	O
into	O
PVDF	O
membrane	O
.	O

After	O
blocked	O
with	O
10	O
%	O
BSA	B-GP
in	O
tris	O
-	O
buffered	O
saline	O
buffer	O
(	O
TBS	O
)	O
for	O
4	O
h	O
at	O
room	O
temperature	O
,	O
the	O
blots	O
in	O
PVDF	O
membrane	O
were	O
incubated	O
overnight	O
with	O
the	O
primary	O
antibodies	B-GP
respectively	O
at	O
4	O
°	O
C	O
.	O

After	O
washed	O
3	O
times	O
by	O
tris	O
-	O
buffered	O
saline	O
buffer	O
with	O
tween	O
20	O
(	O
TBST	O
),	O
the	O
protein	O
blots	O
were	O
labeled	O
with	O
the	O
relevant	O
secondary	O
antibodies	B-GP
conjugated	O
with	O
Horseradish	B-OG
Peroxidase	B-GP
(	O
HRP	B-GP
),	O
and	O
signals	O
were	O
visualized	O
using	O
the	O
HyGLO	O
HRP	B-GP
detection	O
kit	O
from	O
Denville	O
(	O
Metuchen	O
,	O
NJ	O
,	O
USA	O
).	O
β	B-GP
-	I-GP
Actin	I-GP
was	O
measured	O
to	O
control	O
for	O
equal	O
loading	O
.	O

3	O
.	O
6	O
.	O

Quantitative	O
Reverse	O
-	O
Transcription	O
-	O
Polymerase	O
Chain	O
Reaction	O
(	O
RT	O
-	O
PCR	O
)	O

Relative	O
RT	O
-	O
PCR	O
was	O
conducted	O
by	O
TaqMan	O
gene	O
expression	O
master	O
mix	O
from	O
Applied	O
Biosystems	O
(	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
).	O

Briefly	O
,	O
total	O
RNA	O
was	O
isolated	O
from	O
Huh7	O
cells	O
using	O
the	O
RNeasy	O
kit	O
from	O
Qiagen	O
(	O
Valencia	O
,	O
CA	O
,	O
USA	O
).	O

Reverse	O
transcription	O
was	O
performed	O
to	O
synthesize	O
cDNA	O
by	O
the	O
High	O
Capacity	O
cDNA	O
Reverse	O
Transcription	O
Kit	O
from	O
Applied	O
Biosystems	O
(	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
).	O

The	O
TaqMan	O
assays	O
was	O
performed	O
in	O
an	O
ABI	O
7300	O
system	O
using	O
the	O
following	O
profile	O
:	O
95	O
°	O
C	O
for	O
10	O
min	O
followed	O
by	O
40	O
cycles	O
of	O
15	O
s	O
at	O
95	O
°	O
C	O
and	O
60	O
s	O
at	O
60	O
°	O
C	O
.	O

MRC2	B-GP
mRNA	O
levels	O
were	O
normalized	O
to	O
18	O
s	O
rRNA	O
mRNA	O
levels	O
in	O
the	O
same	O
samples	O
.	O

The	O
TaqMan	O
probes	O
for	O
MRC2	B-GP
(	O
Hs00195862_m1	O
)	O
and	O
18s	O
rRNA	O
(	O
Hs99999901_s1	O
)	O
were	O
both	O
from	O
Applied	O
Biosystems	O
.	O

3	O
.	O
7	O
.	O

Scratch	O
Wound	O
Healing	O
Migration	O
Assay	O

Huh7	O
cells	O
were	O
plated	O
into	O
6	O
-	O
well	O
plates	O
and	O
cultured	O
to	O
more	O
than	O
90	O
%	O
confluency	O
.	O

Scratch	O
wound	O
were	O
made	O
by	O
a	O
1000	O
-	O
μL	O
-	O
pipette	O
tip	O
.	O

Images	O
of	O
wounds	O
were	O
taken	O
with	O
a	O
phase	O
-	O
contrast	O
microscope	O
at	O
0	O
,	O
24	O
and	O
48	O
h	O
.	O

Cell	O
migration	O
was	O
quantitated	O
by	O
measuring	O
the	O
width	O
of	O
the	O
scratch	O
wounds	O
.	O

Each	O
experiment	O
was	O
repeated	O
three	O
times	O
.	O

3	O
.	O
8	O
.	O

Invasion	O
Assay	O

Invasion	O
assay	O
was	O
performed	O
using	O
Millicell	O
invasion	O
chambers	O
(	O
8	O
mm	O
pore	O
size	O
)	O
from	O
Millipore	O
Corp	O
(	O
Billerica	O
,	O
MA	O
,	O
USA	O
).	O

Huh7	O
cells	O
was	O
grown	O
in	O
serum	O
-	O
free	O
medium	O
overnight	O
and	O
then	O
plated	O
into	O
the	O
upper	O
chamber	O
pre	O
-	O
coated	O
with	O
basement	O
membrane	O
Matrigel	O
.	O

The	O
Huh7	O
cells	O
were	O
cultured	O
in	O
the	O
upper	O
chamber	O
with	O
serum	O
-	O
free	O
medium	O
and	O
meanwhile	O
the	O
bottom	O
chamber	O
was	O
filled	O
with	O
medium	O
with	O
20	O
%	O
FBS	O
.	O

These	O
cells	O
were	O
cultured	O
at	O
the	O
normal	O
condition	O
.	O

After	O
24	O
h	O
,	O
Huh7	O
cells	O
remaining	O
in	O
the	O
top	O
surface	O
of	O
Matrigel	O
membrane	O
were	O
swabbed	O
carefully	O
and	O
the	O
membrane	O
was	O
fixed	O
with	O
paraformaldehyde	O
for	O
10	O
min	O
.	O

Huh7	O
cells	O
in	O
the	O
membrane	O
was	O
stained	O
by	O
crystal	O
violet	O
solution	O
and	O
observed	O
under	O
microscope	O
.	O

Five	O
fields	O
were	O
selected	O
randomly	O
to	O
get	O
the	O
mean	O
cell	O
number	O
in	O
each	O
membrane	O
.	O

Each	O
exanimation	O
was	O
repeated	O
six	O
times	O
.	O

3	O
.	O
9	O
.	O

Chromatin	O
Immunoprecipitation	O
(	O
ChIP	O
)	O
Assay	O

The	O
ChIP	O
assay	O
was	O
performed	O
as	O
described	O
in	O
the	O
previous	O
study	O
[	O
11	O
].	O

The	O
primers	O
used	O
to	O
detect	O
the	O
MRC2	B-GP
promoter	O
are	O
designed	O
as	O
following	O
:	O
(	O
forward	O
:	O
5	O
'-	O
GTCTCAGTCCTGCCCTATGC	O
-	O
3	O
';	O
reverse	O
:	O
5	O
'-	O
CGAACTGGGGAGTCAGGATG	O
-	O
3	O
').	O

The	O
PCR	O
products	O
were	O
separated	O
by	O
electrophoresis	O
,	O
visualized	O
on	O
a	O
2	O
%	O
agarose	O
gel	O
and	O
compared	O
by	O
the	O
densitometry	O
.	O

Each	O
exanimation	O
was	O
repeated	O
six	O
times	O
.	O

3	O
.	O
10	O
.	O

Statistical	O
Analysis	O

Differences	O
in	O
MRC2	B-GP
protein	O
expression	O
in	O
HCC	B-DS
tissues	O
compared	O
to	O
adjacent	O
liver	O
tissues	O
were	O
compared	O
by	O
the	O
Mann	O
–	O
Whitney	O
U	O
test	O
.	O

The	O
relationship	O
between	O
MRC2	B-GP
,	O
TGFβ1	B-GP
and	O
clinical	O
characteristics	O
of	O
HCCs	B-DS
was	O
assessed	O
using	O
Spearman	O
rank	O
test	O
respectively	O
.	O

Differences	O
between	O
the	O
Kaplan	O
–	O
Meier	O
curves	O
of	O
HCCs	B-DS
with	O
high	O
and	O
low	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
in	O
comparison	O
with	O
adjacent	O
liver	O
tissues	O
were	O
evaluated	O
by	O
the	O
log	O
rank	O
test	O
.	O

Statistical	O
significance	O
was	O
accepted	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

Multivariate	O
analysis	O
was	O
performed	O
using	O
SPSS	O
V17	O
.	O
0	O
software	O
(	O
SPSS	O
Inc	O
.,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
and	O
the	O
PRISM	O
5	O
software	O
(	O
GraphPad	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
was	O
used	O
for	O
other	O
statistical	O
analyses	O
.	O

4	O
.	O

Conclusions	O

HCC	B-DS
is	O
one	O
of	O
the	O
most	O
frequently	O
occurring	O
tumors	B-DS
worldwide	O
in	O
the	O
last	O
decade	O
.	O

The	O
treatment	O
options	O
with	O
curative	O
intent	O
include	O
radical	O
liver	O
resection	O
,	O
local	O
ablation	O
and	O
liver	O
transplantation	O
at	O
the	O
early	O
stage	O
.	O

Unfortunately	O
,	O
most	O
HCC	B-DS
patients	O
present	O
at	O
the	O
advanced	O
stage	O
,	O
which	O
precludes	O
the	O
application	O
of	O
these	O
curative	O
treatments	O
.	O

As	O
the	O
effect	O
of	O
chemotherapy	O
with	O
conventional	O
cytotoxic	O
agents	O
is	O
unsatisfactory	O
,	O
therapy	O
options	O
for	O
patients	O
with	O
advanced	O
HCC	B-DS
are	O
extremely	O
limited	O
.	O

Tumor	B-DS
metastasis	O
is	O
the	O
key	O
death	O
cause	O
of	O
HCC	B-DS
patients	O
at	O
the	O
advanced	O
stage	O
and	O
thus	O
it	O
is	O
urgent	O
to	O
figure	O
out	O
the	O
molecular	O
mechanism	O
of	O
HCC	B-DS
metastasis	O
and	O
identify	O
the	O
novel	O
therapy	O
targets	O
to	O
prevent	O
HCC	B-DS
metastasis	O
.	O

MRC2	B-GP
is	O
a	O
180	B-GP
-	I-GP
kDa	I-GP
type	I-GP
1	I-GP
transmembrane	I-GP
receptor	I-GP
that	O
binds	O
extracellular	O
and	O
intracellular	O
collagens	B-GP
and	O
internalizes	O
them	O
via	O
clathrin	O
-	O
coated	O
pits	O
into	O
early	O
endosomes	O
for	O
lysosomal	O
degradation	O
[	O
23	O
].	O

There	O
have	O
been	O
accumulating	O
studies	O
reported	O
that	O
MRC2	B-GP
expression	O
is	O
increased	O
aberrantly	O
in	O
a	O
variety	O
of	O
cancers	B-DS
and	O
associated	O
with	O
poor	O
prognosis	O
.	O

Sulek	O
et	O
al	O
.	O
detected	O
MRC2	B-GP
expression	O
in	O
112	O
human	B-OG
squamous	B-DS
cell	I-DS
carcinomas	I-DS
and	O
19	O
normal	O
or	O
tumor	B-DS
-	O
adjacent	O
head	O
and	O
neck	O
tissue	O
samples	O
and	O
found	O
that	O
expression	O
of	O
MCR2	O
was	O
increased	O
in	O
tumor	B-DS
stroma	O
compared	O
with	O
tumor	B-DS
-	O
adjacent	O
connective	O
tissue	O
and	O
related	O
positively	O
with	O
poor	O
differentiation	O
[	O
20	O
].	O

After	O
analyzing	O
169	O
prostate	O
tissue	O
sections	O
including	O
benign	B-DS
prostatic	I-DS
hyperplasia	I-DS
and	O
prostate	B-DS
cancer	I-DS
by	O
immunofluorescence	O
assay	O
,	O
Kogianni	O
et	O
al	O
.	O
found	O
that	O
MRC2	B-GP
expression	O
was	O
clearly	O
increased	O
in	O
both	O
stromal	O
tissues	O
and	O
epithelial	O
tissues	O
of	O
prostate	B-DS
cancer	I-DS
compared	O
to	O
benign	B-DS
prostatic	I-DS
hyperplasia	I-DS
[	O
19	O
].	O

In	O
glioblastoma	B-DS
multiforme	I-DS
,	O
it	O
was	O
found	O
that	O
MRC2	B-GP
was	O
over	O
-	O
expressed	O
in	O
tumor	B-DS
tissues	O
and	O
attributed	O
to	O
mediating	O
tumor	B-DS
cells	O
invasion	O
via	O
collagen	B-GP
-	O
containing	O
matrices	O
[	O
24	O
].	O

In	O
this	O
study	O
,	O
we	O
reported	O
for	O
the	O
first	O
time	O
that	O
MRC2	B-GP
expression	O
was	O
significantly	O
higher	O
in	O
HCC	B-DS
tissues	O
than	O
that	O
in	O
adjacent	O
liver	O
tissues	O
and	O
associated	O
with	O
intrahepatic	O
metastases	O
and	O
portal	O
vein	O
invasion	O
.	O

After	O
comparing	O
the	O
Kaplan	O
–	O
Meier	O
curves	O
,	O
we	O
found	O
that	O
higher	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
predicted	O
worse	O
outcome	O
after	O
liver	O
resection	O
.	O

It	O
was	O
consistent	O
with	O
the	O
results	O
from	O
the	O
Palmieri	O
group	O
[	O
17	O
],	O
reporting	O
that	O
MRC2	B-GP
was	O
an	O
accuracy	O
prognostic	O
marker	O
for	O
breast	B-DS
cancer	I-DS
metastases	O
.	O

To	O
determine	O
the	O
mechanism	O
of	O
over	O
-	O
expression	O
of	O
MRC2	B-GP
in	O
HCC	B-DS
,	O
we	O
measured	O
TGFβ1	B-GP
protein	O
expression	O
in	O
the	O
same	O
HCC	B-DS
samples	O
by	O
IHC	O
and	O
found	O
that	O
there	O
was	O
positive	O
correlation	O
between	O
MRC2	B-GP
and	O
TGFβ1	B-GP
expression	O
.	O

TGFβ1	B-GP
treatment	O
leaded	O
to	O
up	O
-	O
regulation	O
of	O
MRC2	B-GP
apparently	O
in	O
vitro	O
,	O
as	O
well	O
.	O

Moreover	O
,	O
we	O
found	O
6	O
potential	O
Smad	B-GP
protein	O
binding	O
sites	O
in	O
the	O
promoter	O
of	O
MRC2	B-GP
gene	O
and	O
verified	O
the	O
direct	O
interaction	O
between	O
Smad	B-GP
protein	O
and	O
the	O
MRC2	B-GP
promoter	O
in	O
HCC	B-DS
cells	O
by	O
ChIP	O
assay	O
.	O

The	O
inhibitor	O
of	O
Smad3	B-GP
SIS3	O
inhibited	O
the	O
effect	O
of	O
TGFβ1	B-GP
treatment	O
on	O
controlling	O
MRC2	B-GP
transcription	O
in	O
HCC	B-DS
cells	O
dramatically	O
.	O

These	O
indicated	O
eventually	O
that	O
MRC2	B-GP
over	O
-	O
expression	O
could	O
result	O
from	O
hyperactivation	O
of	O
TGFβ1	B-GP
/	O
Smad3	B-GP
signaling	O
in	O
HCC	B-DS
.	O

Therefore	O
,	O
it	O
was	O
demonstrated	O
that	O
TGFβ1	B-GP
regulated	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
,	O
which	O
is	O
consistent	O
with	O
the	O
findings	O
in	O
prostate	B-DS
cancer	I-DS
[	O
25	O
]	O
and	O
glioblastoma	B-DS
multiforme	I-DS
[	O
24	O
].	O

As	O
known	O
to	O
all	O
,	O
TGFβ1	B-GP
acts	O
as	O
both	O
promoter	O
and	O
repressor	O
via	O
different	O
cell	O
signaling	O
in	O
tumor	B-DS
pathogenesis	O
.	O

To	O
find	O
the	O
role	O
of	O
MRC2	B-GP
on	O
the	O
TGFβ1	B-GP
paradox	O
about	O
HCC	B-DS
progression	O
,	O
we	O
treated	O
Huh7	O
cells	O
with	O
TGFβ1	B-GP
and	O
found	O
that	O
cell	O
mobility	O
and	O
invasion	O
were	O
enhanced	O
as	O
respected	O
.	O

However	O
,	O
after	O
knockdown	O
of	O
MRC2	B-GP
by	O
siRNAs	O
,	O
the	O
migration	O
and	O
invasion	O
abilities	O
of	O
Huh7	O
cells	O
were	O
not	O
affected	O
by	O
TGFβ1	B-GP
treatment	O
.	O

These	O
data	O
proved	O
strongly	O
that	O
MRC2	B-GP
took	O
an	O
important	O
part	O
in	O
the	O
oncogenic	O
function	O
of	O
TGFβ1	B-GP
in	O
HCC	B-DS
.	O

In	O
summary	O
,	O
this	O
investigation	O
showed	O
that	O
MRC2	B-GP
expression	O
was	O
aberrantly	O
increased	O
in	O
HCC	B-DS
and	O
associated	O
with	O
intrahepatic	O
metastases	O
and	O
portal	O
vein	O
invasion	O
.	O

Additionally	O
,	O
a	O
high	O
level	O
of	O
MRC2	B-GP
in	O
HCC	B-DS
tissue	O
predicted	O
a	O
poor	O
outcome	O
after	O
liver	O
resection	O
.	O

It	O
was	O
demonstrated	O
further	O
that	O
MRC2	B-GP
was	O
regulated	O
directly	O
by	O
TGFβ1	B-GP
/	O
Smad3	B-GP
and	O
involved	O
in	O
the	O
oncogenic	O
effect	O
of	O
TGFβ1	B-GP
in	O
HCC	B-DS
.	O

Detection	O
of	O
MRC2	B-GP
expression	O
in	O
HCC	B-DS
tissues	O
could	O
be	O
very	O
feasible	O
guidance	O
for	O
the	O
diagnosis	O
of	O
HCC	B-DS
invasion	O
and	O
metastasis	O
,	O
also	O
for	O
prediction	O
of	O
outcome	O
after	O
liver	O
resection	O
.	O

